Phaseline

Targets › VEGFR1

VEGFR1 (Vascular endothelial growth factor receptor 1): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 2; Oncology; next expected readout Dec 2026.

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. Acts as a positive regulator of postnatal retinal hyaloid vessel regression (By similarity). (UniProt, P17948)

Open in Phaseline: the race on VEGFR1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Fei GaoDonafenib
Multi-kinase inhibitor targeting FGFR and VEGFR
FGFR1, VEGFR1, VEGFR2, VEGFR3Phase 2Hepatocellular Carcinoma with PVTTDec 2026
Karie RuncieZanzalintinib (XL092)
Multi-targeted receptor tyrosine kinase inhibitor targeting VEGF receptors
VEGFR1, VEGFR2, VEGFR3Phase 2Advanced Renal Cell CarcinomaDec 2027

Conditions

Advanced Renal Cell Carcinoma (1) Hepatocellular Carcinoma with PVTT (1)

Modalities

mixed (1), small molecule (1)

Companies

Karie Runcie (1) Fei Gao (1)

Related targets

VEGFR2 (2) VEGFR3 (2) FGFR1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.